Biomerica (NASDAQ:BMRA) vs. Nano-X Imaging (NASDAQ:NNOX) Head-To-Head Analysis

Nano-X Imaging (NASDAQ:NNOX – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Nano-X Imaging and Biomerica, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nano-X Imaging 1 2 2 1 2.50
Biomerica 1 0 0 0 1.00

Nano-X Imaging presently has a consensus target price of $4.33, indicating a potential upside of 1,783.24%. Biomerica has a consensus target price of $9.00, indicating a potential upside of 718.18%. Given Nano-X Imaging’s stronger consensus rating and higher possible upside, analysts plainly believe Nano-X Imaging is more favorable than Biomerica.

Insider and Institutional Ownership

21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 7.7% of Nano-X Imaging shares are held by insiders. Comparatively, 12.3% of Biomerica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Nano-X Imaging and Biomerica”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nano-X Imaging $15.63 million 1.16 -$75.02 million ($2.14) -0.11
Biomerica $4.45 million 0.76 -$3.78 million ($1.64) -0.67

Biomerica has lower revenue, but higher earnings than Nano-X Imaging. Biomerica is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nano-X Imaging and Biomerica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nano-X Imaging -926.05% -116.93% -100.67%
Biomerica -115.50% -142.81% -77.83%

Volatility and Risk

Nano-X Imaging has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Summary

Nano-X Imaging beats Biomerica on 9 of the 15 factors compared between the two stocks.

About Nano-X Imaging

(Get Free Report)

Nano-X Imaging Ltd. is an Israeli medical technology company developing digital X-ray imaging systems and related services. Its Nanox.ARC system is designed to produce medical images using the company’s digital X-ray technology, with the goal of expanding access to diagnostic imaging. The company’s broader offering includes Nanox.CLOUD, a cloud-based platform intended to connect imaging systems with image-management and diagnostic services, and Nanox.AI, which develops artificial-intelligence tools for analyzing medical images.

About Biomerica

(Get Free Report)

Biomerica, Inc. is a medical diagnostic company that develops, manufactures and markets in vitro diagnostic products. Its tests are designed to help detect and assess a range of health conditions, with a focus on gastrointestinal disorders, food sensitivities and related areas. The company’s offerings include laboratory-based and point-of-care tests, including its inFoods IBS blood test, which is intended to help guide dietary management for people with irritable bowel syndrome. Biomerica also sells diagnostic products for other applications, including infectious and inflammatory conditions.

Receive News & Ratings for Nano-X Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nano-X Imaging and related companies with MarketBeat.com's FREE daily email newsletter.